DOCSLIB.ORG

University of Groningen PET Imaging and in Silico Analyses to Support

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Groningen PET Imaging and in Silico Analyses to Support University of Groningen PET imaging and in silico analyses to support personalized treatment in oncology Moek, Kirsten DOI: 10.33612/diss.112978295 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Moek, K. (2020). PET imaging and in silico analyses to support personalized treatment in oncology. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.112978295 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 30-09-2021 06 The antibody-drug conjugate target landscape across a broad range of tumor types Kirsten L. Moek1, Derk Jan A. de Groot1, Elisabeth G.E. de Vries1, Rudolf S.N. Fehrmann1 1 Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands Ann Oncol. 2017;28:3083-3091 Chapter 06 Abstract Background Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Since ADC tumor cell targets do not have to be drivers of tumor growth, ADCs are potentially relevant for a wide range of tumors currently lacking clear oncogenic drivers. Therefore, we aimed to define the landscape of ADC targets in a broad range of tumors. Materials and methods PubMed and ClinicalTrials.gov were searched for ADCs that are or were evaluated in clinical trials. Gene expression profiles of 18,055 patient derived tumor samples representing 60 tumor (sub)types and 3,520 healthy tissue samples were collected from the public domain. Next, we applied Functional Genomic mRNA-profiling to predict per tumor type the overexpression rate at the protein level of ADC targets with healthy tissue samples as a reference. Results We identified 87 ADCs directed against 59 unique targets. A predicted overexpression rate of ≥ 10% of samples for multiple ADC targets was observed for high incidence tumor types like breast cancer (n = 31 with n = 23 in triple negative breast cancer), colorectal cancer (n = 18), lung adenocarcinoma (n = 18), squamous cell lung cancer (n = 16) and prostate cancer (n = 5). In rare tumor types we observed, amongst others, a predicted overexpression rate of 55% of samples for CD22 and 55% for ENPP3 in adrenocortical carcinomas, 81% for CD74 and 81% for FGFR3 in osteosarcomas, and 95% for c-MET in uveal melanomas. Conclusion This study provides a data driven prioritization of clinically available ADCs directed against 59 unique targets across 60 tumor (sub)types. This comprehensive ADC target landscape can guide clinicians and drug developers which ADC is of potential interest for further evaluation in which tumor (sub)type. 134 The antibody-drug conjugate target landscape across a broad range of tumor types Introduction Despite progress in anticancer drug treatment including molecularly targeted agents that inhibit specific oncogenic “driver” pathways, most patients still die of metastatic disease. Therefore, there remains an unmet need to develop new systemic treatment options to improve survival of cancer patients. Numerous patients fail to benefit from molecularly targeted agents because their tumors lack oncogenic drivers to target. In this context, an interesting emerging class of therapeutics are antibodies bound to a cytotoxic agent, known as antibody- drug conjugates (ADCs). ADC targets do not have to be drivers of tumor growth to be meaningful because they serve as an entry point for the cytotoxic agent. This makes ADCs potentially relevant for a wide range of tumors. After an ADC is bound to its tumor specific molecular target, the cytotoxin is internalized and activated. This allows the selective cellular tumor delivery of a high concentration of the cytotoxin that would cause severe dose-limiting toxicities if administered systemically. To prevent unintended biodistribution the total body target expression should favor the tumor instead of healthy tissues.1 An established example of an ADC is trastuzumab emtansine, which is currently part of standard of care in patients with human epidermal growth factor receptor 2 (HER2) overexpressing 2 metastatic breast cancer. 06 Immunohistochemical (IHC) analyses allows to investigate the protein expression of ADC targets in different tumor (sub)types and healthy tissues. However, large scale IHC analysis for a target is time consuming and demands extensive resources. Therefore, we currently lack data about the expression of ADC targets for numerous tumor types, which impedes potential effective treatment with available ADCs in a significant subset of cancer patients. To this end, we used the recently developed method of functional genomic mRNA profiling (FGmRNA profiling) to predict overexpression rates of ADC targets at the protein level.3 FGmRNA profiling can correct a gene expression profile of an individual tumor for physiological and experimental factors, which are considered not to be relevant for the observed tumor phenotype. In this manuscript, we applied FGmRNA profiling to a large database containing a broad spectrum of different tumor and healthy tissue (sub)types. Subsequently, we used the resulting FGmRNA profiles to prioritize potential ADC targets per tumor (sub) 135 Chapter 06 type. In addition, we present an overview of ADCs which are currently marketed or in clinical development for anti-cancer treatment. Materials and methods Search strategy To identify targets for clinically available ADCs PubMed was searched at the latest April 2017. The following search terms were used: “antibody-drug conjugate”, “cancer”, “tumor” and “oncology” in various combinations, spelling variants and synonyms. The search was limited to manuscripts published in English and involving clinical trials. Reviews were excluded. In addition, ClinicalTrials.gov was searched in April 2017 for on-going studies with ADCs with the search terms [antibody-drug conjugate] AND [cancer]. Finally, abstracts and posters from the ASCO 2015/2016 and ECCO-ESMO 2015 and ESMO 2016 meetings were selected using “antibody-drug conjugate” as search term. Moreover, information on ADCs, ADC targets, linked cytotoxins, tumor type and status of clinical development (phase 1-3) was collected. If we could not find that information in the previously described sources we searched Embase to collect additional information using the name of the identified ADC as term. In case an ADC is in different phases of clinical development for a specific indication, we chose to systematically report the highest phase. Data acquisition Publicly available microarray expression data was extracted from the Gene Expression Omnibus (GEO).4 The analysis was confined to the Affymetrix HG-U133 Plus 2.0 platform (GEO accession identifier: GPL570). Samples were included for analysis if they represented healthy tissue or cancer tissue obtained from patients or healthy individuals and raw data was available. Only tumor (sub)types with ≥ 5 samples were included for analysis. Pre-processing and quality control was performed as previously described.3,5 For the breast cancer cohort receptor status was collected or inferred as described before.5,6 Predicting overexpression rates of ADC targets at the protein level First, we applied FGmRNA profiling to each individual sample, both cancer and healthy tissue. For a detailed description of FGmRNA profiling we refer to Fehrmann et al.3 136 The antibody-drug conjugate target landscape across a broad range of tumor types In short, we analyzed 77,840 expression profiles of publicly available samples with principal component analysis and found that a limited number of “Transcriptional Components” (TCs) capture the major regulators of the mRNA transcriptome. Subsequently, we identified a subset of TCs that described non-genetic regulatory factors. We used these non-genetic TCs as covariates to correct microarray expression data and observed that the residual expression signal (i.e. FGmRNA profile) captures the downstream consequences of genomic alterations on gene expression levels. Subsequently, for each individual gene that is targeted by ADC(s) we determined the percentage of samples per tumor (sub)type with a significant increased FGmRNA signal, which is considered a proxy for protein overexpression. The threshold was defined in the set of FGmRNA profiles of healthy tissues by calculating the 97.5th percentile for the FGmRNA signal
Load more

Recommended publications
  • Polatuzumab Vedotin - R/R DLBCL RG7769 PD1-TIM3 Bimab - Solid Tumors NSCLC RG7446 Tecentriq – Her2-Pos
    Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) 1 Changes to the development pipeline FY 2018 update New to phase I New to phase II New to phase III New to registration 3 NMEs: 2 NMEs transitioned from Ph1 1 NME transitioned from Ph2: 2 NMEs + 1 AI transitioned from Ph2 RG6217 - HBV RG7906 - psychiatric disorders RG6042 HTT ASO - Huntington’s following filing in EU and US: RG6237 - neuromuscular disorders RG6058 tiragolumab + Tecentriq - 6 AIs: RG7596 polatuzumab vedotin - r/r DLBCL RG7769 PD1-TIM3 biMAb - solid tumors NSCLC RG7446 Tecentriq – Her2-pos. BC neoadj RG6268 entrectinib - NSCLC ROS1+ 1 AI: 1 NME starting Ph2 RG7446 Tecentriq – high risk NMIBC RG6268 entrectinib – NTRK1 pan-tumor RG7601 Venclexta + gilteritinib – r/r RG6180 iNeST (personalized cancer RG6152 Xofluza - influenza hosp. patients 3 AIs transitioned from Ph3 following AML vaccine) + pembrolizumab - malignant RG6152 Xofluza – influenza pediatric filing in EU and US: melanoma patients RG7446 Tecentriq + nab-paclitaxel 1L 1 NME following termination of Ph3 RG7601 Venclexta - r/r MM t(11:14) non sq NSCLC RG7412 crenezumab – familial RG7601 Venclexta + HMA/LDAC - 1L RG7446 Tecentriq + nab-paclitaxel Alzheimer’s disease healthy individuals AML* 1LTNBC RG7446 Tecentriq + chemo - 1L extensive 1 AI: stage SCLC RG7446 Tecentriq SC – NSCLC Removed from phase I Removed from phase II Removed from phase III Removed from registration 2 NMEs:
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • The Evolving Concept of Cancer and Metastasis Stem Cells
    JCB: Review The evolving concept of cancer and metastasis stem cells Irène Baccelli1,2 and Andreas Trumpp1,2 1Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), D-69120 Heidelberg, Germany 2Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), D-69120 Heidelberg, Germany The cancer stem cell (CSC) concept, which arose more review is to illustrate the current dynamic view of CSCs to fos- than a decade ago, proposed that tumor growth is sus- ter the development of better therapeutic approaches to target this highly complex and deadly disease. tained by a subpopulation of highly malignant cancerous cells. These cells, termed CSCs, comprise the top of the The classical concept of CSCs tumor cell hierarchy and have been isolated from many Adult regenerating tissues (such as the skin, the gastrointes- leukemias and solid tumors. Recent work has discovered tinal mucosa, or the hematopoietic system) are hierarchically Downloaded from that this hierarchy is embedded within a genetically het- organized (Murphy et al., 2005; Fuchs and Nowak, 2008; van erogeneous tumor, in which various related but distinct der Flier and Clevers, 2009; Seita and Weissman, 2010). At the top of the cellular organization, normal adult stem cells subclones compete within the tumor mass. Thus, geneti- maintain tissues during homeostasis and facilitate their regen- cally distinct CSCs exist on top of each subclone, revealing eration, for example in response to infection or to cell loss a highly complex cellular composition of tumors. The CSC due to injury. These physiological stem cells are defined by concept has therefore evolved to better model the complex their functional properties: they have the life-long capacity to jcb.rupress.org and highly dynamic processes of tumorigenesis, tumor self-renew (the ability to give rise to a new stem cell after cell relapse, and metastasis.
    [Show full text]
  • Molecular Interactions of Erbb Receptor Tyrosine Kinases and Integrin Β1: Implications for Tumor Therapy
    THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy by Miklós Petrás Supervisor: Prof. János Szöllősi, D.Sc. Álmos Klekner, Ph.D. UNIVERSITY OF DEBRECEN DOCTORAL SCHOOL OF MOLECULAR MEDICINE DEBRECEN, 2013 Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy Miklós Petrás Ph.D. Thesis UNIVERSITY OF DEBRECEN MEDICAL AND HEALTH SCIENCE CENTER DEPARTMENT OF BIOPHYSICS AND CELL BIOLOGY DEPARTMENT OF NEUROSURGERY DEBRECEN, 2013. 2 Ph. D. thesis data Title: Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy Author: Miklós Petrás, M.D. Supervisors: Prof. János Szöllősi, D.Sc. Álmos Klekner, M.D., Ph.D. Doctoral School: "Molecular Medicine" at the University of Debrecen Head of Doctoral School: Prof. László Csernoch, D.Sc. Doctoral examination committee: Chairman: Prof. László Csernoch, D.Sc. Members: Prof. Ferenc Erdődi, D.Sc. Beáta Bugyi, Ph.D. Place and time of doctoral examination: Debrecen, 3 May 2013 Doctoral thesis committee: Chairman: Prof. László Csernoch, D.Sc. Reviewers: Prof. István Jóna, D.Sc. József Tóvári, Ph.D. Members: Prof. Ferenc Erdődi, D.Sc. Beáta Bugyi, Ph.D. Place and time of thesis defence: Debrecen, 3 May 2013 Key words: ErbB (EGFR), integrin, tyrosine kinase, FRET, trastuzumab, PI-3K/Akt, breast cancer, astrocytoma (glioblastoma) 3 "Because strait is the gate, and narrow is the way, which leadeth unto life, and few there be that find it." Matthew 7:14 Bible - King James Version, 1611 Oxford King James Bible (Authorized Version), 1769 4 CONTENTS ABBREVIATIONS ....................................................................................................................................
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara
    INN-nimet Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency 1.4.
    [Show full text]
  • Review Article Cd44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches
    Hindawi Contrast Media & Molecular Imaging Volume 2017, Article ID 2709547, 14 pages https://doi.org/10.1155/2017/2709547 Review Article CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches Diana Spiegelberg1 and Johan Nilvebrant2 1 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden 2Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden Correspondence should be addressed to Diana Spiegelberg; [email protected] and Johan Nilvebrant; [email protected] Received 24 February 2017; Revised 23 April 2017; Accepted 21 May 2017; Published 20 June 2017 Academic Editor: Shasha Li Copyright © 2017 Diana Spiegelberg and Johan Nilvebrant. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Head and neck squamous cell carcinoma (HNSCC) is a common and severe cancer with low survival rate in advanced stages. Noninvasive imaging of prognostic and therapeutic biomarkers could provide valuable information for planning and monitoring of the different therapy options. Thus, there is a major interest in development of new tracers towards cancer-specific molecular targets to improve diagnostic imaging and treatment. CD44v6, an oncogenic variant of the cell surface molecule CD44, is a promising molecular target since it exhibits a unique expression pattern in HNSCC and is associated with drug- and radio-resistance. In this review we summarize results from preclinical and clinical investigations of radiolabeled anti-CD44v6 antibody-based tracers: full-length antibodies, Fab, F(ab )2 fragments, and scFvs with particular focus on the engineering of various antibody formats and choice of radiolabel for the use as molecular imaging agents in HNSCC.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]